Galli Giulio, Melcón-Fernández Estela, de Garnica García María Gracia, Martínez-Fernández Beatriz, Dehnavi Mahsa, Andrés Sonia, Pérez-Pertejo Yolanda, Reguera Rosa M, García-Estrada Carlos, Martínez-Valladares María, Balaña-Fouce Rafael
Departamento de Ciencias Biomédicas, Facultad de Veterinaria, Universidad de León, Campus de Vegazana s/n, 24007 León, Spain.
MicrosVeterinaria, C/Profesor Pedro Cármenes, Campus de Vegazana, 24007 León, Spain.
Int J Mol Sci. 2025 Apr 7;26(7):3452. doi: 10.3390/ijms26073452.
New therapeutic molecules for farm animals are needed to address worldwide problems in the food industry, like the rise of resistance among ruminant parasites and pathogenic microbes. Since in vivo testing would involve an excessive number of animals, with consequent ethical and economic issues, the generation of sheep intestinal organoids represents a promising close-to-reality in vitro model for veterinary drug development; however, the characterization and application of such organoids remain limited. In this study, ovine intestinal organoids were generated from adult LGR5+ stem cells from the intestinal crypts of freshly slaughtered lambs, and developed in an in vitro culture system. Morphological analysis via brightfield microscopy and immunocytochemical staining revealed a pseudostratified epithelium with multiple cell types, and distinct apical-basal polarity, while RNA sequencing validated the preservation of the physiological characteristics of the original organ. The development and characterization of a robust and reproducible protocol for culturing sheep duodenum intestinal organoids in a high-throughput screening (HTS) compatible format demonstrated reliability in HTS applications, with Z'-factor tests indicating robust assay performance. Dose-response studies using pre-identified compounds showed comparable pharmacodynamic profiles between mouse and sheep organoids. These findings establish sheep intestinal organoids as an innovative tool for veterinary pharmacology and toxicology, offering a cost-effective and sustainable platform to address challenges such as drug resistance and improve livestock health.
为解决食品行业的全球性问题,如反刍动物寄生虫和致病微生物耐药性的增加,需要新的家畜治疗分子。由于体内试验会涉及大量动物,随之而来的是伦理和经济问题,绵羊肠道类器官的生成代表了一种有前景的、接近现实的兽药开发体外模型;然而,此类类器官的表征和应用仍然有限。在本研究中,从刚宰杀羔羊的肠隐窝中的成年LGR5+干细胞生成绵羊肠道类器官,并在体外培养系统中培养。通过明场显微镜和免疫细胞化学染色进行的形态学分析显示,其具有假复层上皮,包含多种细胞类型,且具有明显的顶端-基底极性,而RNA测序验证了原始器官生理特征的保留。以高通量筛选(HTS)兼容形式培养绵羊十二指肠肠道类器官的稳健且可重复方案的开发与表征证明了其在HTS应用中的可靠性,Z'因子测试表明检测性能良好。使用预先确定的化合物进行的剂量反应研究表明,小鼠和绵羊类器官之间的药效学特征具有可比性。这些发现将绵羊肠道类器官确立为兽药药理学和毒理学的创新工具,为应对耐药性等挑战和改善家畜健康提供了一个经济高效且可持续的平台。